De­flat­ing R&D claims, pros­e­cu­tors say an im­pa­tient Mar­tin Shkre­li con­duct­ed bo­gus drug study in Cyprus

For Mar­tin Shkre­li, the first line of de­fense against his most sav­age crit­ics — which now in­cludes a group of fed­er­al pros­e­cu­tors who would like Judge Kiyo Mat­sumo­to to throw the book at him for three felony con­vic­tions — was his work de­vel­op­ing new drugs for rare dis­eases.

But the feds say that too was noth­ing but a sham, ar­gu­ing that the biotech ex­ec launched an un­su­per­vised tri­al of one of his drugs in Cyprus so he could tout cher­ry picked re­sults to in­vestors in an SEC fil­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER